NCT06107205View on ClinicalTrials.gov

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2023

Conditions
Healthy Adult Subjects
Interventions
DRUG

TTYP01

1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)

DRUG

Radicava

1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)

DRUG

Radicava ORS

1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)

Trial Locations (1)

78209

ICON Early Phase Services, San Antonio

All Listed Sponsors
lead

Shanghai Auzone Biological Technology Co., Ltd.

INDUSTRY

NCT06107205 - Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter